#Zentiva #pharmaceuticals #Czech Republic #Prague #EU Directive

Zentiva's Legal Appeal Against EU Wastewater Directive

In a significant move regarding the availability of pharmaceuticals in Europe, Zentiva, a prominent producer of generic medicines, has lodged an appeal against a ruling by the Court of Justice of the European Union (CJEU) concerning the EU Directive on Urban Wastewater Treatment (UWWTD). This directive remains a contentious issue, raising serious concerns for the pharmaceutical industry and, in particular, for patients relying on affordable medications.

Zentiva's appeal, submitted alongside other players in the unpatented medicine sector, seeks to overturn an earlier decision that deemed the complaint inadmissible, thereby blocking judicial review over substantive points raised when the appeal was first lodged back in March 2025. The main contention centers around the implementation of extended producer responsibility (EPR), which could fundamentally alter the landscape of drug pricing and accessibility.

During discussions at the Employment, Social Policy, Health, and Consumer Affairs Council (EPSCO), representatives from 24 out of 27 EU states expressed reservations about the directive and its potential repercussions. Despite these concerns, the directive continues to undergo national implementation. The problematic aspects of the directive, as highlighted by Zentiva, pose risks to the affordability and availability of essential medications for millions of Europeans.

Zentiva emphasizes that while it supports measures to reduce micro-pollutants in wastewater, it fundamentally opposes the EPR model as outlined in the UWWTD. Such a model could impose undue financial burdens on pharmaceutical and cosmetic manufacturers for cleaning pollutants that they did not create, while other industries remain exempt. This scenario threatens the principle of “the polluter pays” and jeopardizes patient access to critical medications, as generic drugs—a category that constitutes around 70% of medicines dispensed in Europe—face significant operational strains due to stringent price controls and narrow profit margins.

Steffen Saltofte, CEO of Zentiva and president of Medicines for Europe, articulated the urgency of this issue, stating that, “Generic medicines are the foundation of affordable healthcare in Europe. If disproportionate costs are imposed on producers of essential medicines, the supply of these drugs could become economically unviable, ultimately burdening patients.” Furthermore, he noted that protecting the environment should not come at the expense of public health.

The directives suggest that producers take significant responsibility—specifically, at least 80% of the costs associated with advanced cleaning processes. Zentiva argues that existing regulations do not allow for significant modifications to drug compositions, nor do they incentivize the introduction of